TABLE 5.
Microbiological outcomes at TOC visit of ME and MITT patients with MSSA at baseline treated with linezolid or comparator drugsa
| Patient population | % of patients cured (no. cured/total) after:
|
|||
|---|---|---|---|---|
| Treated with linezolid | Randomized to vancomycinb | Receiving vancomycin onlyc | Switched from vancomycin to alternative antibioticd | |
| ME | 84.9 (90/106) | 75.3 (70/93) | 77.3 (17/22) | 74.6 (53/71) |
| MITT | 73 (92/126) | 66.4 (75/113) | 55.6 (20/36) | 71.4 (55/77) |
a
TOC visits occured 7 days after the end of treatment.
b
Patients remained on vacomycin or were switched to an alternative antibiotic.
c
Patients remained on vancomycin.
d
Alternative antibiotics specified in the protocol were nafcillin, oxacillin, dicloxacillin, and flucloxacillin.